Intercure Ltd.
InterCure Ltd. is an Israel-based medical cannabis company operating through its Canndoc subsidiary, with cultivation, manufacturing, and distribution tied together in a vertically integrated seed-to-sale model. Its business centers on GMP-certified, pharmaceutical-grade cannabis products for regulated medical markets, including Israel and selected international markets.
Tilikausi 2024 · muutos edellisvuodesta
Kehitys 2021–2024
Liiketoiminta
Osuus liikevaihdostaCannabis-based products sold for regulated medical use, including flower and related formats.
Growing, harvesting, and preparing cannabis biomass for sale and distribution.
Licensed distribution services and channel access for medical cannabis products.
Asiakkaat
InterCure sells primarily into regulated medical cannabis channels, where patients access products through licensed healthcare and dispensing systems. It also serves institutional and commercial partners in markets where product registration, importation, or local distribution partnerships are needed.
Patients buying physician-recommended cannabis products for regulated medical use.
Licensed outlets that dispense InterCure/Canndoc products to end patients.
Partners that import, register, or distribute products in foreign medical markets.
Potential market access for regulated medical cannabis opportunities only.
Strategia
InterCure’s strategy is to build a multi-country medical cannabis platform by combining domestic strength in Israel with selective expansion into large regulated European markets. It also emphasizes partnerships, product launches, and acquisitions or investments that broaden its research, cultivation, and distribution capabilities.
Diversifies the business beyond Israel and targets larger addressable markets.
New formulations and registrations support channel growth and shelf presence.
Control over cultivation, processing, and distribution supports quality and channel control.
R&D partnerships can improve product development and market differentiation.
Maantiede
InterCure is headquartered in Israel and is anchored by its domestic cannabis operations there, while also building exposure to Germany and other regulated international medical markets. The company has highlighted expansion activity in Europe and a selective review of U.S. opportunities limited to regulated medical cannabis markets.
Riskit
InterCure faces regulatory, market-access, and execution risks that are common to cannabis operators, especially because each market depends on local licensing and product approvals. It also has exposure to geopolitical and operational disruption in Israel, while international growth depends on winning distribution, navigating import rules, and sustaining product quality.
- Regulatory dependenceVaikutus: KorkeaTodennäköisyys: Korkea
Medical cannabis sales depend on licenses, product registrations, and local rules in each market.
Kohdistuu - Geopolitical disruption in IsraelVaikutus: KorkeaTodennäköisyys: Kohtalainen
Core cultivation and management functions are tied to Israel, creating operational disruption risk.
Kohdistuu: Domestic operations and logistics
- Execution risk in international expansionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Growth in Germany and elsewhere requires product launches, local partners, and regulatory approvals.
Kohdistuu: Europe expansion
- Cannabis market pricing pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Medical cannabis markets can see rapid changes in supply, competition, and pricing.
Kohdistuu: Product sales margins and channel economics
- Quality and compliance riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
GMP and pharmaceutical-grade positioning require consistent standards across production and distribution.
Kohdistuu: Manufacturing and product registration
Kirjanpito
Harkinnanvaraiset erätCannabis inventory valuation can change with harvest yield, aging, and market prices.
Vaikutus: Affects gross profit and operating results
Receivables from distributors and partners may require provisioning.
Vaikutus: Affects earnings and balance sheet quality
Management excludes fair-value inventory changes, share-based pay, and impairment items.
Vaikutus: Can materially change the bridge from net income to operating performance
Product launches and market registrations can shift sales between periods.
Vaikutus: Affects comparability across quarters
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
IM Cannabis Corp.
IMCC · Medicinal Chemicals & Botanical Products
IceCure Medical Ltd.
ICCM · Surgical & Medical Instruments & Apparatus
Aurora Cannabis Inc
ACB · Medicinal Chemicals & Botanical Products
Raphael Pharmaceutical Inc.
RAPH · Medicinal Chemicals & Botanical Products
Cannapharmarx, Inc.
CPMD · Pharmaceutical Preparations
Trulieve Cannabis Corp.
TRLV · Medicinal Chemicals & Botanical Products
Päivitetty: 28.9.2026